Team – Oxford Sciences Innovation

Pete joined OSI as the Head of Property in July 2019. Prior to this, he was a Partner at Bidwells, a property consultancy with a focus on the science and technology sector. Pete was previously a Director at Jones Lang LaSalle, an international property consultancy, where he advised Deutsche Bank, GSK and Sony. He also worked with corporate clients for BNP Paribas Real Estate. Pete holds a BA in French and Italian from Bristol University and is a Member of the Royal Institution of Chartered Surveyors. At OSI, Pete is responsible for managing the growing property portfolio and for providing strategic advice to portfolio companies.

Pete Wilder

Head of Property

Central Team

Nick joined OSI as a Principal in July 2020, bringing a decade of experience across investing and corporate finance. Prior to joining OSI he was a Principal at Valiance, a MedTech-focused venture capital firm. He was previously an investor at large cap buyout private equity firm, Nordic Capital. Prior to that he was an investment banker at Bank of America Merrill Lynch. He holds a Triple First Class MA (Cantab) in Natural Sciences from the University of Cambridge. At OSI, Nick is responsible for managing the firm’s relationships with and investments in a number of its portfolio companies. As part of his role he represents OSI on various boards.

Nick Dixon-Clegg

Principal

Investment Team

Aidan joined OSI as an Entrepreneur in Residence in October 2019. He previously ran Business Development for Addepar, a fintech company in Silicon Valley. Prior to this, he worked in cleantech at Hazel Capital and in banking at Goldman Sachs. He also founded Find Circles in 2016, a new online model for peer support around mental health. Aidan holds an MA in English from the University of Oxford. At OSI, Aidan focuses on applied neuroscience.

Aidan Crawley

Entrepreneur in Residence (Health Tech)

Advisors, EiRs & SiRs

Matt joined OSI as a founding Principal in 2015 and focuses on software and software-enabled businesses. An engineer and geek at heart, he was previously a Managing Director at Goldman Sachs, most recently in Strategic Investing and, prior to that, Fixed Income where he built novel pricing models, analytics, and workflow tools. He holds an MSc in Information Engineering from the University of Cambridge and was trained and sponsored by the Ministry of Defence Engineering and Science Group. Matt represents OSI on the boards of Navenio, Mind Foundry, PQShield, Bibliu, Diffblue, OxfordVR, Ultromics, HEXR and Osler.

Matthew Arnold

Principal (AI & Software)

Investment Team

Emily joined OSI in February 2021 as an Associate. Prior to OSI, Emily gained experience in sustainable finance developing ESG data products at Arabesque S-Ray, where she was responsible for managing the product pipeline, representing market needs, and leading product launches. Emily previously worked with the Responsible Investment Association (RIA) as a Research Associate, supporting RIA in their publications. She holds an MPhil in Environmental Policy from the University of Cambridge, where she researched the effect of energy policy on cleantech venture capital investment in Canada. At OSI, Emily works in the Investor Relations, Co-investing, and Communications team.

Emily Matthews

Associate (Investor Relations)

Central Team

Alex joined OSI as Head of Corporate Finance in October 2019. He was previously a medical student at the University of Oxford and a junior doctor in Oxford before joining investment banking in 2007. Over the course of 13 years, he worked on M&A and capital raising across healthcare, as well as energy and infrastructure. He worked at UBS and then Lazard in Europe and the Australia Pacific region. His experience includes both large pharma and medtech clients as well as early stage biotech and digital health, traditional and renewable energy generation and transmission for private and public market clients. At OSI, Alex co-ordinates all fundraising and exits across the portfolio, manages the Investment Committee process and reports on the Investment Portfolio. He represents OSI on the boards of Vaccitech and Macrophox and is an observer on the board of Evox Therapeutics.

Alex Hammacher

Head of Corporate Finance

Central Team

Tinashe joined OSI in 2019 as an Associate. He has a MD/PhD background that combines close to a decade of clinical expertise as a frontline healthcare-worker with doctoral training in public health. Tinashe is a Rhodes Scholar (South Africa-At-Large & Trinity College, 2015), past recipient of the Oxford University Nuffield Department of Surgical Sciences "Best Early Stage researcher of The Year Award" (2019), affiliate of the Royal College of Surgeons and UK Faculty of Pharmaceutical Medicine. At OSI, Tinashe is on the board of Circadian Therapeutics and supports the delivery of the StEP programme.

Tinashe Chandauka

Associate

Investment Team

Jim joined OSI as CFO and Director at the time of founding in 2015 and has been the interim CEO since November 2019. He has over 30 years of experience in the commercial sector. Prior to his role at OSI, Jim was the CFO of a number of listed companies, including Informa Group (where he was a founder director), Sportingbet, Johnson Service Group, and IBC Group. He was also CFO at Lonrho after it was taken private in 2013. He trained as an accountant with Deloitte, where he worked for 8 years. At OSI, Jim works closely with the investment team on all transactions (fundraises and exits) and also oversees all OSI central operations.

Jim Wilkinson

Chief Financial Officer

Central Team

Liliane joined OSI in December 2019 and is a Healthtech Investment Principal. Liliane completed her DPhil in Human Genetics (Canadian Rhodes Scholar, St John’s College 2009) at the Oxford Centre for Diabetes, Endocrinology and Metabolism at the University of Oxford. Since, Liliane has worked across global health diplomacy, innovation policy and genetics research on national and international levels. Liliane previously served as Deputy Head of the UK Foreign Commonwealth Office/NHS joint unit, driving partnerships in medical workforce, digital health and life sciences between the United Kingdom, Latin America, South Africa and South East Asia. Before then, she was a Policy Fellow at the Institute for Global Health Innovation at Imperial College London, advising on adoption of health system innovations in low and middle income countries, with a particular focus on Myanmar. At the World Health Organization, Liliane worked on indigenous and refugee health initiatives in Brazil, Paraguay and the Middle East and coordinated global technical guidance for the use of digital health in diabetes, hypertension and smoking cessation. Liliane is an associate member of the Schmidt Science Fellows Academic Council and established and currently runs the Rhodes Scholarships for Syria, Lebanon, Jordan and Palestine. At OSI, Liliane focuses on healthcare technology and sits on the joint steering committee for Lab10x.

Liliane Chamas

Principal (Healthtech)

Investment Team

Claire joined OSI in September 2019 as a Life Sciences Investment Principal and is on secondment from Biocity, a Life Science incubator network. At Biocity, Claire is an Investment Director and was responsible for the deployment of the Alderley Park Venture Fund, a seed fund developed with AstraZeneca. She has had a varied career across the BioPharmaceutical industry from R&D strategy, licensing, business development and corporate investment, in the UK and US. Notable experience includes roles at UCB Group, Sanofi-Genzyme and AstraZeneca across a diverse range of therapy areas and modalities. Claire serves on the board of a number of Life Science companies, the Enterprise Advisory Board of the University of Liverpool and acts as an advisor for Innovate-UK. Claire received her BSc in Physiology and PhD in Pharmacology in Glasgow. She also holds an MBA focused on entrepreneurship as well as certificates in Investment Management (IMC) and Company Board Direction.

Claire Brown

Principal (Life Sciences)

Investment Team

Alan has been on the board of OSI since its foundation. He is currently CEO of IP Group, a FTSE 250 business that specialises in university spinouts in the US, UK and Australia. He was previously the joint founder and Chief Executive of Techtran Group Ltd, a company that provided outsourced technology services to leading universities. Techtran was acquired by IP Group in 2005. From 1995 to 2002 Alan was a corporate finance partner at KPMG, where he specialised in providing advice to fast growing technology businesses. Alan is also Non-Executive Chairman of Proactis Holdings plc, an AIM-listed software company based in York, Non-Executive Chairman of Ceres Power, an AIM listed fuel-cell company and Non-Executive Director of Oxford Nanopore, a gene sequencing company.

Alan Aubrey

Non-Executive Director

Board

Aneeqa joined the board of OSI in early 2019. She is the CEO and Founder of eporta, an online wholesale, B2B, e-commerce platform for the interior design industry. She was previously the Strategy Director for Zoopla and led the $1bn IPO of the business. Aneeqa began her career in private equity after graduating from university. She was hired by Terra Firma as their youngest employee aged 21, where she was an Investment Analyst. She then went on to work as an Investment Executive at CVC, where she was again the youngest person to join the team, aged 24.

Aneeqa Khan

Non-Executive Director

Board

Dr Robert Easton became an advisor to OSI in 2020. He is a is a former Partner of Carlyle, the global alternative asset management company. During his 19 years at the firm he performed a number of roles as an investment professional, leading investment teams and funds in buyout and technology investing, while serving on multiple portfolio company boards. Robert is a past Chairman of the British Venture Capital Association and a serial investor in technology driven, small and start-up businesses. He’s had a variety of engagements with the higher education sector at Oxford University, where until recently he was a Pro-Vice-Chancellor, as well as at Imperial College, London. In addition to being a Trustee of CRUK, Robert is a Fellow of the British Heart Foundation and a Trustee of the Young Vic Theatre and through his philanthropy funds causes in science, sport, music, higher education, conservation and sub-Saharan Africa.

Robert Easton

Advisor

Advisors, EiRs & SiRs

Ross joined OSI as a Scientist in Residence in May 2020. He was previously a post-doctoral researcher in the Department of Plant Sciences at the University of Oxford. He holds a BA (First) in Biological Sciences from the University and conducted his doctoral research in Interdisciplinary Bioscience. During his DPhil he generated three first author publications, a patent application, and engaged with local start-ups through internship and consultancy opportunities. At OSI, Ross focuses on AgTech and Synthetic Biology with a view to building a new venture in this space.

Ross Hendron

Scientist in Residence (Agtech)

Advisors, EiRs & SiRs

Jack joined OSI as an Accountant in July 2016. He was previously a Business Service Manager at Pearson Buchholz Limited and has eight years of experience in accounting in companies such as CPM UK. He trained as an accountant for three years in Oxford and holds an ACCA. At OSI, Jack is responsible for all aspects of internal finance, including financial reporting, tax planning and treasury management.

Jack Strudley

Accountant

Central Team

Uciane joined OSI as a Principal in December 2019. She was previously an investor and EIR at the US-based fund, Atlas Venture, where she focused on company creation, early-stage investing, and operations within Atlas portfolio companies. She was involved in the launch of two companies, Quench Bio and Dyne Therapeutics, and served on several boards including Navitor, Quench, and Dyne. She also operated within the cell & gene therapy companies Korro Bio and AVROBIO [Nasdaq: AVRO], where she supported/co-led operations and financing, scientific, and commercial strategies. Prior to joining Atlas, Uciane was the Director of BD & Strategy at Compass Therapeutics, a US-based clinical stage I-O/immunology company which launched in 2015 with a $132M Series A led by F-Prime & Orbimed. Prior to Compass, she spent 5 years working with large-small cap biopharma companies in Boston as a commercial strategy consultant. Uciane holds a PhD in cancer immunology from Dartmouth College. At OSI, Uciane currently represents OSI on the boards of T-Cypher, PepGen, MiroBio, Scenic Biotech, and DJS Antibodies and is building new companies in cell therapy, gene therapy, and neurosciences. She is also leading efforts on a pre-seed initiative which may launch in 2021, Pulsar.

Uciane Scarlett

Principal (Life Sciences)

Investment Team

Jas joined OSI as an Investment Associate in July 2020. He previously worked at McKinsey & Co., where he was promoted early to Associate, led the Venture Academy and focussed on strategy projects across the energy, transport and consumer retail industries. Prior to this, Jas interned at Morgan Stanley and the Elton John AIDS Foundation. He holds a BA in Economics & Management from the University of Oxford and won several academic scholarships / prizes during his time there. At OSI, Jas assists the Principals to uncover new opportunities in Deep Tech.

Jas Rajput

Associate (Deep Tech)

Investment Team

Luke joined OSI as a Scientist in Residence in May 2020. He was previously a Head of Department at Immunocore, where he led TCR discovery across the Oncology, Autoimmune and Infectious Diseases pipelines. Prior to Immunocore, Luke was a Research Fellow at the University of Birmingham, investigating T cell and NK cell responses to viruses and virally-associated cancers. Luke holds a PhD in Cancer Immunology and Immunotherapy from the University of Birmingham. At OSI, Luke is part of the Life Sciences team and is currently working with others to build innovative companies in the cell therapy space.

Luke Williams

Scientist in Residence (Life Sciences)

Advisors, EiRs & SiRs

Peter joined OSI as an advisor in 2017. He has extensive experience in growing successful international pharmaceutical and healthcare businesses. Peter was Founder and CEO of Clinigen Group, the FTSE AIM global pharmaceutical and services company. He is currently the Chairman of Benchmark Holdings plc, Enigma Holdings and Mitre Group. He was previously chairman of Ergomed plc, CEO of Penn Pharmaceutical Services and the Executive Vice President of a number of pharmaceutical companies. He co-created Unilabs Clinical Trials International in 1997, which was successfully sold to Icon in 2000. He holds an Executive MBA in Business Administration and Management from the Kellogg School of Management.

Peter George

Advisor

Advisors, EiRs & SiRs

Will joined OSI as a founding Principal in 2015. He has previously worked for the China Britain Business Council in Beijing, E.L.I. Holdings in Chengdu, Text Publishing in Melbourne and as a Publishing Director at Penguin UK. He holds a BA in Philosophy, Politics and Economics from the University of Oxford and an MSc in Economic History from the London School of Economics. Will is responsible for OSI's investments in Alloyed, Animal Dynamics, Brill Power, First Light Fusion, Metaboards, Odqa Renewable Energy Technologies, Orca Computing, Oxford Quantum Circuits, Oxford Ionics, Quantum Motion, Util and YASA. He is a Trustee of Nekton, a marine research foundation.

William Goodlad

Principal (Deep Tech)

Investment Team

Martin joined OSI as a founding Principal in 2015. Prior to this, he ran Gatehouse Capital for almost ten years, a technology corporate finance boutique working with early stage UK technology companies. He began his career in VC as Investment Manager, later Investment Director, at Top Technology Ventures in 1997, where he was part of a team responsible for investments in more than 20 early stage British technology companies, including IP Group, Focus Solutions Group and Arieso. He has also served as NED for King’s Arms Yard VCT since 2011, and as a Director of the HDH Wills 1965 Charitable Trust. He holds an BA in Geography from the University of Oxford and an MBA from Ashridge Management College. At OSI, Martin serves as NED on the boards of Oxford Flow, Bodle Technologies, MoA Technology and Refeyn.

Martin Fiennes

Principal (Deep Tech)

Investment Team

Alexis joined OSI as CIO (Tech) in February 2021 having previously worked with OSI as an advisor. His career as an entrepreneur began in 1997 when he co-founded Oxford University spinout Opsys Limited to pioneer OLED display technology, which later merged with CDT and was listed on the Nasdaq in 2004. Since then, he has founded and led technology companies across a number of sectors – deep tech (materials science), AI/machine learning (computer vision), digital health (cardiology) – combined with a career in investment banking. As well as his own companies, he currently works as an investor, board member and advisor to a number of technology startups.

Alexis Zervoglos

Chief Investment Officer (Tech)

Central Team

Lisa joined OSI as Senior Communications Manager in September 2020. Prior to this she was Communications Manager for Medicines Discovery Catapult, responsible for translating complex science into simple but compelling stories, championing innovative technologies and new approaches to reshape drug discovery. Lisa has nearly 10 years’ experience working within the pharmaceutical and biotechnology industries. This includes supporting US-based start-up biotechs, entrepreneurs and innovators to define their offering; producing professional and creative communications to attract investment. Lisa holds a BSc in Psychology and an MSc focused on Developmental Cognitive Neuroscience from Durham University. At OSI Lisa will tell our story – promoting our portfolio, the ground-breaking technologies, people and companies that create them.

Lisa Bedwell

Senior Communications Manager

Central Team

Andre joined the board of OSI in early 2020. He is an experienced deep tech advisor with a background in investment banking. He was previously Managing Director, Global Head of Equity Trading at Deutsche Bank, where he worked from 1994 to 2016. After leaving investment banking, Andre founded Braavos Partners, an IT and biotech investment firm. He sits on the board of Singapore Biotech and Next Biosciences and was previously on the board of Deep Science Ventures and Genesis Genetics. He sits on the board of portfolio companies Osler, Ultromics and PQShield.

Andre Crawford-Brunt

Non-Executive Director

Board

Alexis joined OSI as Chief Executive Officer in October 2020. He brings over 25 years of science, technology, and investment experience. Prior to OSI, Alexis worked for leading European venture capital firm Atomico, advising portfolio companies across Europe and the US on their growth strategies and scaling. He originally trained as a doctor at Oxford University before embarking on a business career, including notable senior management and board experience at Virgin, Orange, Candover, RED, the AIDS charity founded by Bono, Wattbike, the world’s most advanced indoor bike, and Spoke, the men’s online clothes business. He helped launch Virgin Mobile and Virgin Active as well as helping Orange to become the top mobile operator in the UK. At OSI Alexis will build on the momentum and success to date, leading the team to create a world leading science and technology business.

Alexis Dormandy

Chief Executive Officer

Central Team

Caroline joined OSI in September 2019 as Executive Assistant to Kate O’Brien, Head of Legal and Company Secretary. She was previously EA to Judy Craymer, Creator and Producer of Mamma Mia! (Show & Films). Prior to this, Caroline was EA to Elliott Bernerd, Founder and Chairman of Chelsfield, a property development and investment company. Caroline holds a BA in History from the University of Nottingham. At OSI, Caroline provides full support to Kate, including diary and event management, document management and administration. Caroline manages the administration of the OSI Board of Directors, including the organisation of board and committee meetings and papers, and the OSI shareholder register.

Caroline Offord

EA to Head of Legal & Company Secretary

Central Team

James joined OSI in October 2020 as an interim Life Sciences Investment Principal, bringing venture capital investment, corporate and board experience focused on healthcare in the UK and internationally. Prior to OSI, James was Head of Corporate Advisory at Mercia Asset Management. Before this, he was Investment Director at Fosun Pharma in China, responsible for venture capital investments, including university IP commercialisation funds and spin-out companies. This built on his experience as Investment Manager at NBGI Ventures, where he focused on medical technology and served on the board of several portfolio companies in the UK, Europe and the US. He entered venture capital after starting his career at Cambridge Consultants in 2006. James holds an EPSRC-funded MPhil in Computational Biology from the University of Cambridge. He is a Mentor on the MedTech SuperConnector led by Imperial College London and a Fellow of the Royal Society of Arts. At OSI James focuses on life science businesses and represents OSI on the boards of Oxford Nanoimaging and SpyBiotech.

James Wong

Principal (Life Sciences)

Investment Team

Sam joined OSI in November 2019 as an Associate. Sam was previously a Strategy Consultant at Monitor Deloitte, focusing on Artificial Intelligence engagements. Prior to this, Sam interned at Elixirr Consulting and in private equity with Abris Capital Partners in Eastern Europe. Sam holds a BA (First) in Philosophy, Politics and Economics from the University of Oxford, where he was an academic scholar and was awarded the Gladstone Scholarship for outstanding performance in PPE. He is also a Fellow of the Royal Society of Arts, Manufactures and Commerce. At OSI, Sam assists the Principals to uncover new opportunities in AI and software.

Sam Harman

Associate (AI & Software)

Investment Team

Professor Bell has represented the University on the board of OSI since its foundation. He is the Regius Professor of Medicine at the University of Oxford. He was the founder of the Wellcome Trust Centre for Human Genetics and has played a key role in the expansion of biomedical research at the University. He now leads the development of the Medical Sciences Division’s research strategies and plays a major role in external relations. Professor Bell is NED at Roche Holding, and Chairman of the Bill & Melinda Gates Foundation Global Health Advisory Board. He sits on the board of Genomics England and chairs its Science Advisory Committee. He was President of The Academy of Medical Sciences from 2006 to 2011 and is a founding Director of three biotech start-ups. Professor Bell trained in Medicine at the University of Oxford, where he specialised in genetics and immunology. He is a Rhodes scholar.

Prof. Sir John Bell

Non-Executive Director

Board

Jo joined OSI as interim CFO in January 2020. He has 13 years experience in a range of finance roles at Sanofi, most recently in Budapest as CFO of the Hungarian affiliate. His other roles at Sanofi include Financial Controller for Sanofi’s European business based in Paris and Head of Controlling & Pricing in the UK & Ireland. Prior to Sanofi, Jo was Finance Manager at the Swiss Biotech Serono and trained as an accountant during 4 years at Unilever. He holds an MA in Physiological Sciences from Oxford. At OSI, Jo is supporting various internal finance activities with a focus on process improvement and efficiency.

Jo Shelley

Finance Consultant

Central Team

Zabrina joined OSI in May 2019 as an Interim Office Manager and began her role as Special Projects Manager in September 2019. She is experienced in working with C-level executives, having been an Executive Assistant at Servcorp and Cult NYC and Front of House Supervisor at Net-a-Porter. Zabrina originally trained in musical theatre at the Royal Academy of Music and performed in various West End and touring shows. At OSI, Zabrina manages various OSI affiliated projects, including the set up and launch of the Grassroots co-working space.

Zabrina Norry

Office Manager & Comms Assistant

Central Team

Kate joined OSI in 2017. Before joining, Kate practiced at Herbert Smith Freehills in London and Paris. Prior to this, she worked as an attaché to the British Embassy in Paris. Kate holds an MA in Jurisprudence from the University of Oxford, and spent a year studying Spanish Law and Catalan Law at the Universitat Pompeu Fabra in Barcelona. At OSI, Kate provides guidance to the team on the negotiation and execution of investments, as well as general corporate, commercial and IP matters. She is also OSI’s company secretary and advises the Board on corporate and governance matters. She has a keen interest in regulatory and policy reform in the deep tech and venture space, and leads OSI’s engagement in this area. Kate is passionate about advancing female corporate representation and entrepreneurship, and is currently spearheading OSI’s commitment to the Investing in Women Code.

Kate O'Brien

Principal, Head of Legal & Company Secretary

Central Team

Peter has been on the board of OSI since its foundation. He is a Senior Partner and Head of Developed Markets Strategy at Landsdowne Partners and has worked for the company for 18 years. Prior to this, he was a Director at Merrill Lynch Investment Managers and a Fund Manager at Mercury Asset Management. Peter is also a member of the investment committee the Oxford University Endowment Fund.

Peter Davies

Non-Executive Director

Board

Charo joined OSI in July 2020 as Project Co-ordinator. Charo has experience in supporting startups as a coordinator of the Oxford University Innovation (OUI) Incubator. Prior to OUI, Charo worked in academic publishing for over 20 years. She led teams delivering training programmes in digital publishing for suppliers across Europe, US and Asia. She was also a business development advisor (VSO-CUSO volunteer) for agriculture micro-enterprises in the Lindl region of Tanzania. Charo is a Lean Six Sigma Green Belt Practitioner. She has a BA in Geography and History and a Postgraduate Certificate in Education from the Universidad Complutense of Madrid. At OSI, Charo manages the Student Entrepreneurship Programme (StEP) and the Frontier Series portfolio accelerator programme.

Charo Bajo

Project Co-ordinator

Central Team

Jeanette joined OSI as an Office Manager and EA to Jim Wilkinson, CFO, in March 2016. She previously worked as an administrator at various placements through Allen Associates. Prior to this, Jeanette spent many years as the Bursary Secretary at an independent school in Kent. She trained as a legal secretary and was previously an administrator for various pension providers. At OSI, Jeanette is the executive assistant to Jim Wilkinson and is responsible for general office management.

Jeanette Lovis

EA to Chief Executive Officer & Chief Financial Officer

Central Team

Walter joined OSI in December 2017, while completing his MEng (First) in Engineering at the University of Oxford. He is currently researching a DPhil in Artificial Intelligence and Robotics at the Oxford Robotics Institute. At OSI, he works as an Analyst under the AI & Software and Healthtech principals. His time is spent in technical due diligence, parsing papers and code, and in aiding OSI’s early stage investments.

Walter Goodwin

Analyst (AI & Software)

Investment Team

Isabel joined OSI as an advisor in November 2019. She is one of just a handful of female General Partners in the UK in her role as Partner at Luminous Ventures, an early-stage deep tech fund focused on human health (healthcare, life sciences, agriculture, food and wellness). Her portfolio at Luminous Ventures includes Synthace, Mahana, Phenomic, Temporall, Hadean, Optellum, Ellipsis, Vital Health, Huma and OxfordVR. Before venture capital, Isabel founded two corporate communications firms focused on the venture ecosystem (two exits), co-founded two software start-ups (one exit) and was an active angel investor in the UK and US.

Isabel Fox

Advisor

Advisors, EiRs & SiRs

Gaelle joined OSI as an Executive Assistant in February 2017. She is experienced in working in administration in Oxford, having been an Administrative Assistant at Oxford Archaeology Limited and previously a Broadcast Assistant at Balliol College. At OSI, Gaelle is the executive assistant to the life sciences team and coordinates OSI events.

Gaelle Akkouche

EA to Life Sciences & Events Coordinator

Central Team

Polly joined OSI as Head of Investor relations, Co-investing and Communications in September 2020. She has over fifteen years’ experience in public equity markets, working across research and equity sales roles for a number of investment banks. The majority of her career was spent at UBS, where she joined as a media analyst during the TMT boom and moved on to lead Telecom and Media equity specialist sales. At UBS she built strong relationships with key equity investors and led the sales effort on a number of prominent IPOs. More recently, Polly has worked with public companies to help sharpen their investor messaging and strengthen their shareholder bases. For the past five years, she has led Investor Relations and Corporate PR at FTSE 250 group Electrocomponents, during a period of leadership change and significant transformation for both the equity story and shareholder base.

Polly Elvin

Head of Investor Relations & Co-investors

Central Team

Amy joined OSI in March 2021 as an Associate in the HeathTech team. Previously, Amy worked as a business consultant with EY Embryonic in the Global Strategy and Transactions practice, helping clients define strategies to future proof their businesses. Amy also brings perspectives from corporate innovation having developed early-stage ideas in liquid biopsy and biosensors at Merck KGaA. In parallel, Amy worked on several Software and AI grassroot concepts that received recognition from Global leaders including the European Space Agency, European Institute of Innovation and Technology and EY Global Innovation. Amy holds a DPhil in Neuroscience from the University of Oxford. At OSI, Amy assists the Principals to uncover new opportunities in HealthTech.

Amy Kao

Associate (Healthtech)

Investment Team

Bernard has represented the University on the board of OSI since its foundation. He has over 30 years of experience in advising UK and international transactions. He was previously Vice-Chairman of JPMorgan and CEO of Evercore Partners International, where he remains the Chairman. He is a retired member of the Council of the University of Oxford and a member of the University’s Remuneration Committee, Finance Committee, Mathematical, Physical and Life Sciences Division Board and Medical Sciences Division Board. He is Chairman of the Ashmolean Museum Board of Visitors, Chairman of the Royal Commission for the Great Exhibition of 1851, Chairman of Garsington Opera, Chairman of the Advisory Board of the Royal Society, a Director of the ERA Foundation and a member of the Advisory Board of Networked Quantum Information Technologies. He is Deputy Steward of Oxford University, Deputy Lieutenant of Oxfordshire and an Honorary Fellow of St. John’s College. He holds an MA from the University of Oxford and is a Fellow of the Royal Society of Chemistry.

Bernard Taylor

Non-Executive Director

Board

Chris joined OSI in December 2019. He is a seasoned biotech entrepreneur with over 35 years’ experience in the biotechnology industry. Chris has considerable expertise in leading and growing early stage companies and their transition to mid-stage clinical development organisations. He has extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity. Chris was formerly a Partner at Syncona, a FTSE250 company, where he was also founding CEO of Achilles Therapeutics. Prior to that he was CEO of Argenta Discovery (sold to Galapagos) and Pulmagen Therapeutics. Chris has a PhD from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).

Chris Ashton

Advisor

Advisors, EiRs & SiRs

Damian joined OSI in January 2021 as an Entrepreneur in Residence. He was previously Director, R&D and Head of Early Drug Discovery for Neuroscience at AstraZeneca Biopharmaceuticals. Prior to that he pursued a clinician-scientist role in neurodegeneration, combining training in neurology at Addenbrookes hospital with basic research at the Department of Genetics and affiliated to the Cambridge Institute for Medical Research. Damian continues to lecture at the University of Cambridge and UCL where he is an Honorary Associate Professor. He is also a founder of GPnotebook.co.uk, the UK’s premier professional medical reference resource, and pursued project spin-outs while at AstraZeneca. At OSI, Damian will provide in-house neuroscience consultancy and expertise, and aims to identify credible scientific breakthroughs to form the basis of an innovative new portfolio company.

Damian Crowther

Entrepreneur in Residence (Life Sciences)

Advisors, EiRs & SiRs

Chris has been on the board of OSI since its foundation and became Executive Chairman in February 2020. He has extensive experience in leading and advising global financial institutions. He is currently Chairman of Lonrho, the African conglomerate, and Leonteq. He is also a member of the supervisory board of Swiss Prime Site and a Senior Advisor to Lone Star Europe. Chris started his career in investment banking at Barclays de Zoete Wedd. He was Head of European Equity Capital Markets at Credit Suisse before becoming CEO of Man Investments, the global hedge fund, and member of the Man Group’s main board. He is also a fellow of the Royal Society of Arts.

Chris Chambers

Chairman

Board

Sive joined OSI as Legal Counsel in June 2020. She was previously an Associate at Marriott Harrison, where she focused on venture capital investments. Sive holds an LLB (Law) from the University of Southampton and LLM (Corporate Law) from UCL. At OSI, Sive works closely with the investment team on the negotiation and execution of new and follow-on investments. She also assists with general corporate, commercial and IP matters.

Sive Ozer

Legal Counsel

Central Team

Giles has represented the University on the board of OSI since its foundation. He has over 35 years of experience in finance and growing technology-based companies, with a particular interest in life sciences. He has worked at main board level in a number of sectors, mainly with large international organisations (inc. public FTSE 100 and FTSE 250 companies) and the University of Oxford. He was formerly the CFO of the University of Oxford, a position he held from 2005 to 2018. He is currently a Director of Arix, Chairman of the audit committees of Arix, Senior and Paypoint and a member of the audit committees of Abcam and Adaptimune Therapeutics. He was previously a Director at Oxford University Innovation, CFO of Amersham and an audit partner with Arthur Anderson & Co.

Giles Kerr

Non-Executive Director

Board

Vishal joined OSI as an advisor in October 2019. He has experience in investment at the intersection of life sciences and engineering. He is an investor at Draper Esprit, where he has led investments in some of Europe’s leading digital healthcare companies, including Clue, PushDR, Lifesum and Evonetix. He is also a Director at Horizon Discovery and Sensyne Health. Vishal is Chairman of the Digital Health Forum and serves on Innovate UK’s Major Award committee. Vishal has previously worked at Atlas Venture, The Wellcome Trust and Radiant Capital. He trained in Medicine at the University of Oxford and received his postgraduate medical training at Imperial College London. He is a Rhodes scholar.

Dr. Vishal Gulati

Advisor

Advisors, EiRs & SiRs

Sally joined OSI in February 2021 as an Associate in the Life Sciences team. She was previously an Anderson Cancer Center Postdoctoral Fellow at the Rockefeller University in New York where her research focussed on genetic instability at the very earliest stages of cancer development. Prior to that, she completed a PhD at the Francis Crick Institute in London where she uncovered an important role for polyploid cells in driving cancer evolution. Academic research that Sally has contributed to has been published in leading journals including Nature Genetics, Nature Communications and Cancer Discovery. At OSI, Sally assists the Principals to uncover new opportunities in Life Sciences.

Sally Dewhurst

Associate (Life Sciences)

Investment Team